To analyze the clinical spectrum and explore optimal treatment strategies to significantly improve the prognosis of thyroid lymphoma (TL).
Key Findings:
67.2% of patients had concurrent Hashimoto’s thyroiditis.
The TL+ group showed more frequent subdiaphragmatic and perivascular lymph node involvement compared to the iTL group (p<0.001 and p=0.003, respectively).
1-, 3-, and 5-year overall survival (OS) rates were 85.0%, 78.4%, and 75.6%, respectively.
Diffuse large B-cell lymphoma (DLBCL) was the most common subtype, accounting for 60.7% of cases.
Age ≥60 years and C-myc expression ≥50% were independent risk factors for shorter progression-free survival (PFS).
Chemotherapy was associated with improved PFS and OS, while surgery alone was linked to shorter PFS.
Interpretation:
TL with extrathyroidal involvement requires Ann Arbor staging-guided management, and chemotherapy significantly improves survival outcomes in patients with thyroid DLBCL, highlighting the need for tailored treatment approaches.
Limitations:
Retrospective design may introduce bias, potentially affecting the reliability of the findings.
Limited sample size may restrict the generalizability of findings to broader populations.
Lack of randomized controlled trials to guide treatment strategies limits the strength of recommendations.
Conclusion:
The study provides valuable insights into the clinical features and prognostic factors of TL, emphasizing the critical role of chemotherapy in improving patient outcomes and suggesting areas for future research.
